banda transcan 2 2016ul

An integrated European platform to conduct translational studies in myelodysplastic syndromes based on the EuroBloodNet infrastructure

Project Coordinator:
Matteo Giovanni Della Porta (Italy), IRCCS Humanitas Research Hospital Cancer Center Rozzano - Milan

Project Partners:
Pierre Fenaux (France), Hôpital St Louis / Université Paris 7, Service d'hématologie séniors, Paris
Uwe Platzbecher (Germany), Technical University of Dresden, Dresden
Francesc Sole (Spain) Josep Carreras Leukaemia Research Institute (IJC), Barcelona

Project Abstract:
RATIONALE. Myelodysplastic syndromes (MDS) are rare cancers with unmet medical needs. Study of MDS has been rapidly transformed by genome characterization. 
HYPOTHESIS. We hypothesize that comprehensive analyses of large patient population will allow to correctly estimate the effect of each mutation on clinical outcomes, and that niche factors and immune dysfunctions may influence the development of MDS, clonal evolution and response to treatments
AIMS. 1- Investigate gene mutations, niche factors and immune dysfunctions influencing the development of MDS, and define biomarkers for early identification of individuals at risk; 2- Develop prognostic models for MDS patients through integration of comprehensive genomic/clinical information; 3- Define biomarkers to better stratify the individual probability of response to specific treatments
METHODS. EuroBloodNet, the European Reference Network in rare hematological diseases, will provide a basis for research activities - AIM1: study of genomic features of clonal dominance in elderly subjects enrolled in 3 large population-based studies and description of the dynamics of clonal establishment and evolution; study of bone marrow microenvironment to identify immune dysfunctions influencing MDS development - AIM2: development of inclusive statistical models to accurately predict clinical outcome at individual level, based on large MDS populations with comprehensive genomic/clinical data - AIM3: analysis of mutational screening and immune profiles from patients enrolled in prospective trials, to provide evidence on genetic/immunologic profiles associated with probability of response to specific compounds
EXPECTED RESULTS. To characterize how clonal hematopoiesis relates to the induction of MDS clinical phenotype, and to test the utility of gene sequencing to detect subjects at risk of developing MDS. To define effective prognostic systems and biomarkers to stratify the individual probability of response to treatment.


(Project funded under JTC 2017)


A new TRANSCAN-2 brochure, highlighting key achievements, is available for download

The 3rd and final TRANSCAN-2 symposium on Tumour Heterogeneity was held in Milan on October 24th
The symposium included talks from the funded consortia of JTC2014, co-funded by the EU (see the abstract book), an exciting discussion on the impact and added value of transnational collaborations on cancer research and a poster prize competition for young scientists.
The event was hosted by Regione Lombardia, Italy with the collaboration of Fondazione Regionale per la Ricerca Biomedica
For further information please contact:



Newsletter 9, December 2019
Newsletter 8, May 2019
Newsletter 7, October 2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, December 2017
Newsletter 3, September 2017
Newsletter 2, April 2017
Newsletter 1, December 2016

To subscribe to the TRANSCAN-2 newsletter please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.